Indication
Stage IV Non-Hodgkin Lymphoma
Aliases
Ann Arbor Stage IV Non-Hodgkin Lymphoma
6 clinical trials
30 products
10 drugs
Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening ProtocolStatus: Recruiting, Estimated PCD: 2027-09-30
Product
EnsartinibProduct
ErdafitinibProduct
LarotrectinibProduct
OlaparibProduct
PalbociclibProduct
SamotolisibProduct
SelpercatinibProduct
SelumetinibProduct
TazemetostatProduct
TipifarnibProduct
UlixertinibProduct
VemurafenibClinical trial
A Phase I Study of ABT-888 in Combination With Cyclophosphamide in Solid Tumors or Non-Hodgkin LymphomaStatus: Active (not recruiting), Estimated PCD: 2021-09-03
Drug
cyclophosphamideProduct
DoxorubicinProduct
VeliparibClinical trial
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: PRIMEStatus: Terminated, Estimated PCD: 2020-12-10
Product
AbemaciclibProduct
AbirateroneProduct
AfatinibDrug
AtezolizumabProduct
BicalutamideProduct
BortezomibProduct
DabrafenibProduct
CabazitaxelProduct
DacomitinibProduct
CabozantinibProduct
DasatinibProduct
DarolutamideDrug
UTD1Drug
AN0025Drug
CelecoxibProduct
CobimetinibProduct
CopanlisibDrug
R-CHOPProduct
EnasidenibDrug
EntrectinibProduct
EnzalutamideDrug
ErlotinibClinical trial
A Phase I/II Trial of Vorinostat (SAHA) (NSC-701852) in Combination With Rituximab-CHOP in Patients With Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL)Status: Active (not recruiting), Estimated PCD: 2015-12-30
Drug
VarlilumabDrug
VincristineProduct
VorinostatClinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Tazemetostat in Patients With Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF ComplexStatus: Active (not recruiting), Estimated PCD: 2022-03-31
Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of LY3023414 in Patients With Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2023-09-30